Novel Eudragit® -based polymeric nanoparticles for sustained release of simvastatin

Página do item simplificado
dc.creatorDeborah Fernandes Rodrigues
dc.creatorRenê Oliveira do Couto
dc.creatorRubén Dario Sinisterra Millán
dc.creatorCarlos Eduardo de Matos Jensen
dc.date.accessioned2023-12-11T15:19:06Z
dc.date.accessioned2025-09-09T01:30:26Z
dc.date.available2023-12-11T15:19:06Z
dc.date.issued2020
dc.description.sponsorshipOutra Agência
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1590/s2175-97902019000418363
dc.identifier.issn2175-9790
dc.identifier.urihttps://hdl.handle.net/1843/61869
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofBrazilian Journal of Pharmaceutical Sciences
dc.rightsAcesso Aberto
dc.subjectQuímica farmacêutica
dc.subjectPolímeros na medicina
dc.subjectMedicamentos -- Biodisponibilidade
dc.subjectMedicamentos -- Dissolução
dc.subjectEstatinas (Agentes cardiovasculares)
dc.subjectSistemas de distribuição de medicamentos
dc.subjectNanopartículas
dc.subject.otherSimvastatin
dc.subject.otherNanoparticles
dc.subject.otherPoly-methylmethacrylate
dc.subject.otherDissolution
dc.subject.otherDrug delivery systems
dc.titleNovel Eudragit® -based polymeric nanoparticles for sustained release of simvastatin
dc.typeArtigo de periódico
local.citation.volume56
local.description.resumoThis paper reports on the development of nanoparticles aiming at the in vitro controlled release of simvastatin (SVT). The nanoparticles were prepared by the nanoprecipitation method with polymers Eudragit® FS30D (EDGFS) or Eudragit® NE30D (EDGNE). EDGFS+SVT nanoparticles showed mean size of 148.8 nm and entrapment efficiency of 76.4%, whereas EDGNE+SVT nanoparticles showed mean size of 105.0 nm and entrapment efficiency of 103.2%. Infrared absorption spectra demonstrated that SVT incorporated into the polymer matrix, especially EDGNE. Similarly, the differential scanning calorimeter (DSC) curve presented no endothermic peak of fusion, indicating that the system is amorphous and the drug is not in the crystalline state. The maintenance of SVT in the amorphous state may favors its solubilization in the target release sites. In the in vitro dissolution assay, the SVT incorporated into the EDGFS+SVT nanoparticles showed a rapid initial release, which may be related to the pH of the dissolution medium used. Regarding the EDGNE+SVT nanoparticles, the in vitro release occurred in a bimodal behavior, i.e., an initial “burst” followed by a sustained delivery, with the kinetics of drug release following Baker-Lonsdale’s mathematical model. All these features suggest the nanoparticulate system’s potential to modulate SVT delivery and enhance its bioavailability.
local.identifier.orcidhttps://orcid.org/0000-0003-1406-0007
local.identifier.orcidhttps://orcid.org/0000-0002-3748-3427
local.identifier.orcidhttps://orcid.org/0000-0001-7656-1849
local.publisher.countryBrasil
local.publisher.departmentICX - DEPARTAMENTO DE QUÍMICA
local.publisher.initialsUFMG
local.url.externahttps://www.scielo.br/j/bjps/a/VHzcCPtQRBdQDFhQtxT7kLq/

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Novel Eudragit® -based polymeric nanoparticles for sustained release of simvastatin.pdf
Tamanho:
783.95 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG